Microdosing Semaglutide and Tirzepatide: Protocols, Dosing Charts, and What Nobody Tells You

You've decided to try microdosing your GLP-1. Maybe your nausea is unbearable at full dose. Maybe you hit your goal weight and want to step down without rebounding. Maybe you're an athlete who needs appetite suppression without losing the ability to fuel training. Whatever the reason, you're here because the standard "take it once a week" protocol doesn't fit your situation anymore.

This guide covers the practical side of microdosing semaglutide, tirzepatide, and retatrutide: common protocols people actually use, what the pharmacokinetics say about splitting doses, the real-world results people report, and how to manage the added complexity without losing track of your schedule.

No fluff, no sales pitch. Just the reference material you'll want to bookmark.

Split Dosing vs. Microdosing vs. Dose Stretching

These three terms get used interchangeably online, but they mean different things. Getting this right matters because each strategy has different goals and different risks.

You can combine strategies. For example, taking a lower total weekly dose and splitting it into two injections. This guide covers all three, but focuses primarily on split dosing and microdosing since those are the most discussed in the GLP-1 community.

Important: All of these approaches are off-label. FDA-approved semaglutide and tirzepatide protocols are once-weekly only. Nothing in this article is medical advice. Always discuss protocol changes with your prescriber.

Why People Microdose (The Real Reasons)

The microdosing trend didn't start in a doctor's office. It started in communities like r/Ozempic, r/tirzepatidecompound, and r/GLP1microdosing where people were solving real problems in real time. Here's what actually drives it:

1. Side effects are dose-dependent and peak-dependent

GLP-1 nausea, vomiting, and fatigue are worst in the 24-48 hours after injection, when blood concentration is highest. Splitting a 2.5mg tirzepatide dose into two 1.25mg injections lowers that peak by roughly 30-40%. For many people, that's the difference between functional and bedridden. This is the single most common reason people experiment with split dosing, especially at higher dose tiers (10mg+ tirzepatide, 2.4mg semaglutide).

2. Maintenance after weight loss (the rebound problem)

The STEP-1 extension trial showed that participants regained approximately two-thirds of their lost weight within a year of stopping semaglutide. Going from a therapeutic dose to nothing is a recipe for rebound. Instead, many people step down to a maintenance microdose: 0.25-0.5mg semaglutide per week, or 2.5mg tirzepatide, just enough to maintain appetite regulation without the full side effect profile. Think of it as a slow off-ramp instead of driving off a cliff.

3. Athletes and active users need to eat

Bodybuilders, CrossFitters, and endurance athletes want the metabolic benefits (improved insulin sensitivity, better body composition) without the appetite suppression that kills their ability to fuel training. A full therapeutic dose can make it physically difficult to consume 2,500+ calories. A microdose provides a subtler effect: you still have appetite control, but you can actually eat enough to train and recover. This is especially common in the biohacking community where people are already comfortable managing complex injection protocols.

4. Cost management

Brand-name GLP-1s run $900-1,300/month without insurance. Even compounded versions cost $200-400/month. Stretching a single vial across more weeks by using a lower weekly dose cuts monthly cost significantly. This is particularly common among people who've hit their target weight and want to maintain without paying full price for a dose they no longer need.

5. Medication sensitivity (hyper-responders)

Some people get significant appetite suppression and side effects even at the lowest starting dose (0.25mg semaglutide or 2.5mg tirzepatide). For these hyper-responders, splitting even the starter dose into two injections makes the medication tolerable. Without this option, they'd have to stop entirely.

Semaglutide Split-Dose and Microdose Protocols

These are the most commonly discussed semaglutide microdosing protocols. None are FDA-approved. Always work with your prescriber.

Practical tip: If you're splitting semaglutide 2x/week, space injections 3-4 days apart (e.g., Monday AM and Thursday PM). This gives more even blood levels than, say, Tuesday and Wednesday.

Tirzepatide Split-Dose and Microdose Protocols

Tirzepatide (Mounjaro/Zepbound) has a shorter half-life than semaglutide (~5 days vs ~7 days). This means blood levels drop more between weekly injections, making split dosing arguably more justified pharmacokinetically.

Practical tip: If you're splitting tirzepatide 2x/week, inject Monday AM and Thursday PM. For 3x/week, space evenly: Monday, Wednesday, Friday. The shorter half-life means spacing matters more than with semaglutide.

Retatrutide: The Next-Gen Protocol

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It's currently in Phase 3 clinical trials (TRIUMPH-1) and is not yet FDA-approved for any indication. Despite this, it's generating massive interest in bodybuilding and biohacking communities for its reported effects on fat loss and body composition.

Because retatrutide is still experimental, there is no established dosing protocol. However, the clinical trial data and community discussions provide some reference points:

Split dosing is discussed for retatrutide largely due to the reported side effect profile, which includes nausea, diarrhea, and appetite suppression that some users describe as more intense than semaglutide or tirzepatide at comparable efficacy levels. The glucagon receptor activity is unique to retatrutide and may contribute to different side effect timing.

What the Pharmacokinetics Actually Say

There are no randomized controlled trials on microdosing or split-dosing GLP-1 medications. Everything in the community is built on pharmacokinetic reasoning and anecdotal data. Here's the science that exists:

Semaglutide (half-life: ~7 days)

The long half-life means weekly dosing already produces relatively stable blood levels. By day 4-5 after injection, you're still at roughly 60-70% of peak concentration. The pharmacokinetic case for splitting semaglutide is weaker than for tirzepatide. But the peak reduction argument is real: splitting the dose lowers the day 1-2 spike that drives the worst nausea. If side effects are your primary concern, split dosing can reduce peak concentration by 30-40% while maintaining similar trough levels.

Tirzepatide (half-life: ~5 days)

The shorter half-life means blood levels drop more significantly between weekly injections. By day 6-7, you're at a meaningfully lower percentage of peak than with semaglutide. Splitting tirzepatide into 2x/week produces noticeably more stable blood levels, with less of a "rollercoaster" between peak and trough. This is why split dosing is more commonly discussed, and arguably more pharmacokinetically justified, for tirzepatide.

The difference becomes much clearer with tirzepatide:

What doctors are saying (2026)

A growing number of obesity medicine specialists acknowledge that split dosing is happening and that some patients benefit from it. The consensus remains cautious: it's not officially recommended, but it's not contraindicated. The key concern is ensuring patients maintain an effective total weekly dose and don't inadvertently under-dose themselves into losing efficacy.

What People Actually Report

Here's what the GLP-1 communities on Reddit, Discord, and various forums consistently say about microdosing. This is anecdotal, not clinical data, but it represents thousands of real-world data points.

The Maintenance Problem (and How to Solve It)

This might be the most important section if you're past the weight loss phase. The data on stopping GLP-1 medications is sobering:

• STEP-1 extension: Participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within a year.
• SURMOUNT-1 follow-up: Tirzepatide discontinuation showed similar rebound patterns, with most weight regain occurring in the first 6 months.
• Community pattern: People who taper gradually report significantly better weight maintenance than those who stop abruptly.

The emerging consensus in the community is that GLP-1s may be a chronic medication for many people, similar to blood pressure meds. If that's the case, finding the lowest effective maintenance dose becomes critical for long-term cost, side effect burden, and sustainability.

A practical maintenance taper

The most common approach people report: once you hit your goal weight and maintain it for 4-8 weeks at your current dose, drop one dose tier. Hold that for another 4-6 weeks. If weight stays stable, drop again. Continue until you find your floor, the lowest dose where your weight remains stable and appetite stays regulated. For semaglutide, many people land at 0.25-0.5mg/week. For tirzepatide, 2.5mg/week is a common maintenance floor.

The key: You need objective data, not just how you feel. Track your weight weekly. If you see a consistent upward trend over 3-4 weeks after a dose reduction, your maintenance dose is probably the tier above. Without tracking, you won't notice the slow creep until you've regained 10+ pounds.

This is where having actual data beats vibes. "I feel fine" is not a maintenance strategy when the research shows two-thirds of people rebound.

Why Microdosing Is Harder to Manage

Here's the part nobody talks about. Microdosing adds real complexity to your protocol, and the margin for error shrinks.

With standard weekly dosing, you set one reminder and inject once. With microdosing, everything multiplies:

• More injection days to remember. Two or three injections per week means more opportunities to forget, double-dose, or lose track of your schedule.
• Smaller doses = bigger percentage errors. Drawing 5 units instead of 20 leaves less room for error. A one-unit mistake at 5 units is a 20% dosing error. At 20 units, it's 5%.
• You need to verify the lower dose is actually working. Are you still losing weight? Has appetite regulation changed? Without tracking, you're guessing, and guessing on an off-label protocol isn't great.
• Side effect patterns change with split dosing. Instead of one bad day per week, you might have two milder days. You need to track this to confirm the protocol is actually an improvement.
• Weekly totals matter more. Missed a dose? Your weekly total is lower than planned. Over a month, those missed doses compound. You need to know your actual weekly total, not just what you intended to inject.

What to track on a microdosing protocol

Stop managing your microdose protocol manually

Set your schedule once. Regimen tells you what to inject, when, and exactly how many units to draw. Smart reminders for every dose, not just once a week.

• Set a weekly target and frequency — Regimen calculates each dose for you
• Built-in split-dose scheduling (Mon AM / Thu PM, or any custom days)
• Automatic syringe unit calculations for any concentration
• Smart reminders for every injection, not just once a week

Get Regimen

Risks and What to Watch For

Microdosing isn't risk-free. Be aware of these before changing your protocol:

Reduced efficacy

Lower doses may not provide the same weight loss or glucose control as therapeutic doses. The FDA-approved dosing was determined through clinical trials to be the minimum effective dose for most people. Going below that means you might not get the results you're expecting.

Accuracy at small volumes

Drawing 3-5 units on an insulin syringe is technically challenging. The smaller the volume, the larger the percentage error from imprecise technique. If your microdose requires drawing less than 5 units, consider whether a different concentration would give you a more practical draw volume.

The "I feel fine, I'll stop" trap

Some people microdose their way down to nothing and then stop entirely. Feeling fine is not the same as maintaining your weight. Without tracking your weight and appetite patterns, you might not notice gradual regain until you've put back 10-15 pounds. Track your trends even on a microdose, especially during a taper. Objective data beats subjective feelings.

Off-label status

Microdosing is not FDA-approved. Your prescriber may not support it. Insurance won't cover off-label protocols. If you run into problems, you're operating outside established guidelines.

Frequently Asked Questions